# A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer

Source: https://onco.cc/trials/nct06953999/  
OnCo record `nct06953999` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gemcitabine and Ivonescimab in pancreatic ductal adenocarcinoma, run by Akeso, now recruiting.

## Summary

A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer is a phase 3 interventional study registered as NCT06953999 by Akeso, with 999 participants planned, started 2025-06-11 and due to reach its primary completion in 2027-05-14. Interventions recorded: Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine, Ivonescimab, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine and Ivonescimab Placebo, AK117 Placebo, Albumin-bound Paclitaxel, Gemcitabine.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06953999
- Phase: 3
- Setting: A Randomized, Controlled, Multi-center Phase III Clinical Study of Ivonescimab Plus Chemotherapy With or Without AK117 Versus Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Cancer
- Sponsor: Akeso
- Enrolled: 999

## Sources

- ClinicalTrials.gov NCT06953999: https://clinicaltrials.gov/study/NCT06953999

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct06953999.json